PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07K 16/42, 16/28, A61K 39/395, A61P 37/00, 17/00, 11/06, G01N 33/577, 33/68

A1

(11) International Publication Number: WO 00/63252

(43) International Publication Date: 26 October 2000 (26.10.00)

(21) International Application Number: PCT/EP00/03288

(22) International Filing Date: 12 April 2000 (12.04.00)

(30) Priority Data:
9908533.4 14 April 1999 (14.04.99) GB

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT m.b.H. [AT/AT]; Brunner Strasse 59, A–1230 Vienna (AT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KRICEK, Franz [AT/AT]; Ulmenweg 9, A–2362 Biedermannsdorf (AT). STADLER, Beda [CH/CH]; Bubenbergplatz 8, CH–3007 Bern (CH). VOGEL, Monique [CH/CH]; Heckenweg 8, CH–3007 Bern (CH).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH–4002 Basel (CH).

(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.



G00001

(54) Title: ANTI–IDIOTYPIC ANTIBODIES AGAINST ANTIBODIES WHICH INHIBIT THE BINDING OF IMMUNOGLOBULINE TO ITS HIGH AFFINITY RECEPTOR

(57) Abstract

Antibodies and antibody fragments which are anti–idiotypic to an antibody that interferes with the binding of the Cε3 region of IgE to its high affinity receptor (mimobodies), particularly, which are anti–idiotypic to BSW17 (BSW17–mimobodies) are described, as well as their use as pharmaceuticals, especially vaccines, in the treatment of IgE–mediated diseases.



162162